39232-05-8Relevant articles and documents
Electrochemical driven water oxidation by molecular catalysts in situ polymerized on the surface of graphite carbon electrode
Wang, Lei,Fan, Ke,Daniel, Quentin,Duan, Lele,Li, Fusheng,Philippe, Bertrand,Rensmo, H?kan,Chen, Hong,Sun, Junliang,Sun, Licheng
, p. 7883 - 7886 (2015)
A simple strategy to immobilize highly efficient ruthenium based molecular water-oxidation catalysts on the basal-plane pyrolytic graphite electrode (BPG) by polymerization has been demonstrated. The electrode 1@BPG has obtained a high initial turnover frequency (TOF) of 10.47 s-1 at ～700 mV overpotential, and a high turnover number (TON) up to 31600 in 1 h electrolysis.
SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
-
Page/Page column 67; 68, (2013/09/12)
The present invention relates to a compound of formula (1-1 ) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Synthesis and Pharmacology of a Series of 3- and 4-(Phosphonoalkyl)pyridine- and piperidine-2-carboxylic Acids. Potent N-Methyl-D-aspartate Receptor Antagonists
Ornstein, Paul L.,Schaus, John M.,Chambers, John W.,Huser, Diane L.,Leander, J. David,et al.
, p. 827 - 833 (2007/10/02)
We recently prepred a series of 3- and 4-(phosphonoalkyl)pyridine- and piperidine-2-carboxylic acids as antagonists of neurotransmission at N-methyl-D-aspartate (NMDA) preferring receptors.NMDA antagonists may prove to be useful therapeutic agents, for instance, as anticonvulsants, in the treatment of neurodegenerative disorders such as Alzheimer's disease and in the prevention of neuronal damage that occurs during cerebral ischemia.The compounds prepared were evaluated for their ability to displace CPP binding (an assay shown to be selective for compounds that bind at the NMDA receptor) and for their ability to block NMDA-induced lethality in mice (an assay that is also specific for competitive and noncompetitive NMDA antagonists).Two of the compounds, cis-4-(phosphonomethyl)piperidine-2-carboxylic acid (11a) and cis-4-(3-phosphonoprop-1-yl)piperidine-2-carboxylic acid (11c) proved to be potent NMDA antagonists. 11a and 11c displaced CPP binding with IC 50's of 95 and 120 nM, respectively, and both protected mice from NMDA-induced lethality, with MEDs (minimum effective dose, the dose at which three of the five animals tested survived) of 10 and 40 mg/kg ip, respectively.The rest of the compounds prepared were weakly active or inactive in these assays.The pattern of activity observed for this series parallels that observed for the acyclic series of ω-phosphono-α-amino acids, where AP5 and AP7 possessed NMDA antagonist activity while AP6 and AP8 were inactive.Reduction of conformational mobility by incorporation of the piperidine ring led to enhanced potency relative to the acyclic analogues.
